Abstract 6 Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell Transplant Access and Outcomes for Patients with Hematologic Malignancies in the U.S.

INTRODUCTION: Patients with hematologic malignancies (HM) who are eligible for allogeneic hematopoietic cell transplant (allo-HCT) often lack an HLA-matched related donor (MRD) and rely on unrelated donors for a matched or mismatched unrelated donor (MUD or MMUD) or on umbilical cord blood (UCB). It...

Descripción completa

Detalles Bibliográficos
Autores principales: Gergis, Usama, Khera, Nandita, Edwards, Marie Louise, Song, Yan, Sun, Rochelle, Simantov, Ronit, Sivaraman, Smitha, Manghani, Rocio, Signorovitch, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trials – Hematopoietic Stem Cell Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446946/
http://dx.doi.org/10.1093/stcltm/szac057.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446946/
http://dx.doi.org/10.1093/stcltm/szac057.006

Ejemplares similares